Cargando…
Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908420/ https://www.ncbi.nlm.nih.gov/pubmed/33504081 http://dx.doi.org/10.3390/ijerph18031058 |
_version_ | 1783655709634723840 |
---|---|
author | Carmona, Antonio Muñoz-Quiles, Cintia Stuurman, Anke Descamps, Alexandre Mira-Iglesias, Ainara Torcel-Pagnon, Laurence Díez-Domingo, Javier |
author_facet | Carmona, Antonio Muñoz-Quiles, Cintia Stuurman, Anke Descamps, Alexandre Mira-Iglesias, Ainara Torcel-Pagnon, Laurence Díez-Domingo, Javier |
author_sort | Carmona, Antonio |
collection | PubMed |
description | The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies. |
format | Online Article Text |
id | pubmed-7908420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79084202021-02-27 Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project Carmona, Antonio Muñoz-Quiles, Cintia Stuurman, Anke Descamps, Alexandre Mira-Iglesias, Ainara Torcel-Pagnon, Laurence Díez-Domingo, Javier Int J Environ Res Public Health Article The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies. MDPI 2021-01-25 2021-02 /pmc/articles/PMC7908420/ /pubmed/33504081 http://dx.doi.org/10.3390/ijerph18031058 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Carmona, Antonio Muñoz-Quiles, Cintia Stuurman, Anke Descamps, Alexandre Mira-Iglesias, Ainara Torcel-Pagnon, Laurence Díez-Domingo, Javier Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title | Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title_full | Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title_fullStr | Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title_full_unstemmed | Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title_short | Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project |
title_sort | challenges and adaptation of a european influenza vaccine effectiveness study platform in response to the covid-19 emergence: experience from the drive project |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908420/ https://www.ncbi.nlm.nih.gov/pubmed/33504081 http://dx.doi.org/10.3390/ijerph18031058 |
work_keys_str_mv | AT carmonaantonio challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT munozquilescintia challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT stuurmananke challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT descampsalexandre challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT miraiglesiasainara challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT torcelpagnonlaurence challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject AT diezdomingojavier challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject |